98%
921
2 minutes
20
Bronchiectasis is a heterogeneous lung disease. There is an increasing focus on personalised medicine in bronchiectasis, with targeted pharmacological interventions for inflammation, immunology and infection. Airway clearance techniques (ACTs) are non-pharmacological treatments used to manage bronchiectasis. Approximately half of patients with bronchiectasis perform ACTs. There have been attempts to personalise ACT prescriptions, including consideration of patient physiology, disease status and psychosocial factors. Guidelines suggest that patient preference or choice should be considered when prescribing ACTs. There is a lack of literature showing patient preference or choice being taken into consideration when prescribing ACTs in bronchiectasis. This article discusses the role of shared decision-making (SDM), the potential use of SDM for ACTs in bronchiectasis to support patient choice of and adherence to ACTs and the steps involved in designing an SDM intervention for ACTs in bronchiectasis for future research. Development and use of an SDM intervention to support patient choice of ACT in bronchiectasis may result in a patient-centred, pragmatic approach to empower patients to be actively involved in their care, improve their knowledge on the importance of ACTs and support improvement in adherence to this essential therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410678 | PMC |
http://dx.doi.org/10.1136/bmjresp-2024-003049 | DOI Listing |
ERJ Open Res
September 2025
Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
https://bit.ly/44jcdWz.
View Article and Find Full Text PDFBMJ Open Respir Res
September 2025
Newcastle University, Newcastle Upon Tyne, UK.
Bronchiectasis is a heterogeneous lung disease. There is an increasing focus on personalised medicine in bronchiectasis, with targeted pharmacological interventions for inflammation, immunology and infection. Airway clearance techniques (ACTs) are non-pharmacological treatments used to manage bronchiectasis.
View Article and Find Full Text PDFAntimicrob Agents Chemother
August 2025
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
The historical model, which posits that β-lactams inhibit bacterial growth while β-lactamase inhibitors (BLIs) merely protect β-lactams from enzymatic degradation, fails to fully explain their activity against (). This study demonstrates that synergistic effects extend beyond the traditional one β-lactam + one BLI paradigm, refuting the oversimplified mechanistic framework. First, β-lactam-based BLIs such as clavulanic acid, sulbactam, and tazobactam exhibit intrinsic antibacterial activity against .
View Article and Find Full Text PDFCureus
February 2025
Department of Cardiovascular and Respiratory Physiotherapy, Ravi Nair Physiotherapy College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
This case report discusses the physiotherapy management of an adult patient with chief complaints of breathlessness and difficulty expelling out mucus for the past month, with a history of multiple hospitalizations due to recurrent respiratory infections, who was diagnosed as bronchiectasis. In this study, the patient was treated with a combination of the RC-Cornet PLUS (CEGLA Medizintechnik, Montabaur, Germany), an oscillatory positive expiratory pressure (OPEP) device used for airway clearance, and the POWERbreathe Medic Plus (POWERbreathe, England, UK), an inspiratory muscle training (IMT) device, along with tailored pulmonary rehabilitation. Pulmonary rehabilitation focused on patient education, breathing exercises, airway clearance techniques (ACTs), endurance training, strengthening, and energy conservation techniques.
View Article and Find Full Text PDFPediatr Pulmonol
January 2025
Department of Physiotherapy, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Background: Regular airway clearance techniques (ACTs) and exercise are recommended for children with bronchiectasis, but current clinical practice and their predictors are unknown.
Objective: We aimed to describe current use of ACTs and exercise among Australian children with bronchiectasis and identify associated predictors.
Methods: Physiotherapy-specific data of 397 children (median age = 8 were extracted from the Australian Bronchiectasis Registry.